MTN-042, or the DELIVER study, is a Phase IIIb open-label study being planned that will evaluate the dapivirine vaginal ring and Truvada as daily PrEP (pre-exposure prophylaxis) in pregnant women to determine whether use of these products is safe for both women and their infants. The study will be conducted at trial sites in Malawi, Uganda, South Africa and Zimbabwe. Of the 750 women who will be enrolled, 500 will use the vaginal ring. The study is the first to be conducted of the dapivirine ring during pregnancy.
The DELIVER and B-PROTECTED Studies: Preventing HIV in Pregnant and Breastfeeding Women
21-March-2019
See Also
Meeting Report: Stakeholders Consultation on MTN-042